Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SOS1 Inhibition Enhances the Efficacy of KRASG12C Inhibitors and Delays Resistance in Lung Adenocarcinoma.

Cancer research - 2 Jan 2025

Daley Brianna R, Sealover Nancy E, Finniff Bridget A, Hughes Jacob M, Sheffels Erin, Gerlach Daniel, Hofmann Marco H, Kostyrko Kaja, LaMorte Joseph P, Linke Amanda J, Beckley Zaria, Frank Andrew M, Lewis Robert E, Wilkerson Matthew D, Dalgard Clifton L, Kortum Robert L

Abstract excerpt

The clinical effectiveness of KRASG12C inhibitors (G12Ci) is limited both by intrinsic and acquired resistance, necessitating the development of combination approaches. Here, we identified targeting proximal receptor tyrosine kinase signaling using the SOS1 inhibitor (SOS1i) BI-3406 as a strategy to improve responses to G12Ci treatment. SOS1i enhanced the efficacy of G12Ci and limited rebound receptor tyrosine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lung Neoplasms
Share to Neoplastic Stem Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Adenocarcinoma of Lung

Share to Drug Resistance, Neoplasm

Share to Kelch-Like ECH-Associated Protein 1

Share to Proto-Oncogene Proteins p21(ras)

Share to SOS1 Protein

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 39437166
DOI: 10.1158/0008-5472.CAN-23-3256
PMCID: PMC11695159

Genes

SOS1
KEAP1
STK11
SOS2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SOS1 Inhibition Enhances the Efficacy of KRASG12C Inhibitors and Delays Resistance in Lung Adenocarcinoma.PMID 39437166Read ↗

SOS1 inhibition enhances the efficacy of and delays resistance to G12C inhibitors in lung adenocarcinomaSemantic proximity Read ↗

Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance.Semantic proximity Read ↗

SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status.Semantic proximity Read ↗

Breaking Oncogene Addiction: Getting RTK/RAS-Mutated Cancers off the SOS.Semantic proximity Read ↗

SOS1: tracking the evolving path from promising to actionable therapeutic target in RAS-dependent cancers.Semantic proximity Read ↗

BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition.Semantic proximity Read ↗

SOS1 inhibition suppresses the emergence of osimertinib resistance to generate a durable response in EGFR-mutant lung cancer.Semantic proximity Read ↗

A Potent SOS1 PROTAC Degrader with Synergistic Efficacy in Combination with KRASG12C Inhibitor.Semantic proximity Read ↗

Resistance looms for KRAS G12C inhibitors and rational tackling strategies.Semantic proximity Read ↗

Differential Response and Resistance to KRAS-Targeted Therapy.Semantic proximity Read ↗

Acquired Resistance to KRASG12C Inhibition in Cancer.Semantic proximity Read ↗

Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.